OncoMatch/Clinical Trials/NCT06365853
A Study of Ocular Toxicity Evaluation and Mitigation During Treatment With Mirvetuximab Soravtansine in Participants With Recurrent Ovarian Cancer With High Folate Receptor-Alpha Expression
Is NCT06365853 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including Mirvetuximab Soravtansine and Lubricating Eye Drops for recurrent ovarian cancer.
Treatment: Mirvetuximab Soravtansine · Lubricating Eye Drops · Prednisolone acetate ophthalmic suspension 1% eye drops · Brimonidine tartrate ophthalmic solution eye drops — The purpose of this study is to evaluate the incidence rate and severity of prespecified mirvetuximab soravtansine (MIRV)-related ocular treatment-emergent adverse events (TEAEs) and assess prophylaxis strategies in all participants (symptomatic and asymptomatic) undergoing prospective ophthalmic evaluation with recurrent ovarian cancer (participants with either platinum-sensitive ovarian cancer \[PSOC\] or platinum-resistant ovarian cancer \[PROC\]) with high folate receptor alpha (FRα) expression.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Other
Cancer type
Ovarian Cancer
Biomarker criteria
Required: FOLR1 high expression (≥ 75% cells with ≥ 2+ membrane staining intensity by VENTANA FOLR1 Assay) (≥ 75% cells with ≥ 2+ membrane staining intensity)
FRα positive (FRα high) as defined by either the VENTANA FOLR1 (FOLR-2.1) IUO Assay, or the VENTANA FOLR1 ( FOLR1-2.1) RxDx Assay (≥ 75% cells exhibit ≥ 2+ membrane staining intensity)
Allowed: BRCA1 mutation (tumor or germline)
Participants with known breast cancer susceptibility gene (BRCA) mutations (tumor or germline) must have received poly (ADP-ribose) polymerase inhibitors (PARPi)
Allowed: BRCA2 mutation (tumor or germline)
Participants with known breast cancer susceptibility gene (BRCA) mutations (tumor or germline) must have received poly (ADP-ribose) polymerase inhibitors (PARPi)
Demographics
Prior therapy
Must have received: poly (ADP-ribose) polymerase inhibitor
Participants with known breast cancer susceptibility gene (BRCA) mutations (tumor or germline) must have received poly (ADP-ribose) polymerase inhibitors (PARPi)
Cannot have received: FRα-targeting agent (mirvetuximab soravtansine)
Participants who received prior treatment with MIRV or other FRα-targeting agents
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of California Los Angeles /ID# 269339 · Los Angeles, California
- Norton Cancer Institute - St. Matthews /ID# 269070 · Louisville, Kentucky
- Holy Cross Hospital - Silver Spring /ID# 269344 · Silver Spring, Maryland
- Mercy David C. Pratt Cancer Center /ID# 269350 · St Louis, Missouri
- The Center Of Hope /ID# 269348 · Reno, Nevada
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06365853 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior FRα-targeting agent disqualifies patients from enrollment.
Does this trial require FOLR1?
Yes, FOLR1 high expression (≥ 75% cells with ≥ 2+ membrane staining intensity by VENTANA FOLR1 Assay) is a required biomarker for enrollment.
Is this trial open to male patients?
No. This trial enrolls female patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify